Liaoning Heiske Pharmaceutical Co., Ltd. has 335 employees, including 4 masters, 90 undergraduates and 93 junior college students, and various professional technicians 187. The company has more than 20,000 square meters of workshops and supporting facilities that meet the national GMP standards. It has 8 professional production lines, including small-volume injections, freeze-dried powder injections, cephalosporin aseptic raw materials and cephalosporin aseptic preparations, glass bottle infusion and multi-chamber bag infusion. The company has obtained the registration documents of seven varieties, such as nalmefene hydrochloride injection and cefodizime sodium for injection, issued by the State Food and Drug Administration, and nalmefene hydrochloride injection has obtained the new drug certificate issued by the State Food and Drug Administration; Small-volume injection workshop, sterile powder injection workshop and large-volume injection workshop successfully passed the national GMP certification, and the products were produced and sold that year, which gained a good social reputation. Sichuan Heiske Pharmaceutical Co., Ltd. is a production base of oral preparations and APIs under Heiske Pharmaceutical Group, located in Wenjiang Strait Science and Technology Park, Chengdu, Sichuan Province, with a total investment of 75 million yuan and an area of more than 30,000 square meters.
At present, the company has more than 20 new drugs in three categories, involving cardiovascular diseases, liver diseases, diabetes and other fields, based on providing the latest and best quality drugs for domestic patients.
The company has established many production lines such as capsules, tablets, granules and raw materials. Taking the implementation of the new GMP as an opportunity, Sichuan Haisike strives to build the enterprise into a domestic first-class modern pharmaceutical R&D and manufacturing base that meets the standards of FDA and CGMP of the European Union.